Cyclacel Pharmaceuticals (NASDAQ:CYCC) Receives New Coverage from Analysts at assumed coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCCFree Report) in a research note released on Saturday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, Roth Mkm cut their target price on Cyclacel Pharmaceuticals from $21.00 to $11.00 and set a buy rating on the stock in a research note on Friday, May 3rd.

Read Our Latest Stock Analysis on Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals Price Performance

Shares of NASDAQ CYCC opened at $2.29 on Friday. Cyclacel Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $13.20. The stock’s 50 day simple moving average is $2.13 and its 200 day simple moving average is $3.11.

Cyclacel Pharmaceuticals (NASDAQ:CYCCGet Free Report) last announced its earnings results on Tuesday, May 14th. The biotechnology company reported ($2.27) earnings per share for the quarter, beating the consensus estimate of ($4.93) by $2.66. The firm had revenue of $0.03 million for the quarter. Cyclacel Pharmaceuticals had a negative return on equity of 1,009.04% and a negative net margin of 4,401.34%. During the same period in the previous year, the firm earned ($7.05) EPS. Sell-side analysts expect that Cyclacel Pharmaceuticals will post -6.32 earnings per share for the current year.

Cyclacel Pharmaceuticals Company Profile

(Get Free Report)

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.

Featured Articles

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with's FREE daily email newsletter.